Comparison of incidences of cardiovascular events among new users of different statins: A retrospective observational cohort study

Current Medical Research and Opinion

Volumn 25, Issue 11, 2009, Pages 2621-2629

  Heintjes, Edith M ^a   Penning van Beest, Fernie J A ^a   Johansson, Saga ^b,c   Stalenhoef, Anton F ^d   Herings, Ron M C ^a,e  

^a PHARMO INSTITUTE FOR DRUG OUTCOMES RESEARCH   (Netherlands)

^b ASTRAZENECA R AND D   (Sweden)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^e ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Cardiovascular events; Daily practice; Dyslipidaemia; Incidence; Myocardial infarction; Observational; Statins

Indexed keywords

ATORVASTATIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; FEMALE; FOLLOW UP; HEART INFARCTION; HOSPITALIZATION; HUMAN; INCIDENCE; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; OBSERVATIONAL STUDY; RETROSPECTIVE STUDY; REVASCULARIZATION; RISK REDUCTION; STROKE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTICHOLESTEREMIC AGENTS; CARDIOVASCULAR DISEASES; COHORT STUDIES; FEMALE; FLUOROBENZENES; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; INCIDENCE; MALE; MIDDLE AGED; NETHERLANDS; PYRIMIDINES; RETROSPECTIVE STUDIES; SULFONAMIDES; TIME FACTORS; YOUNG ADULT;

EID: 72549100794     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990903269112     Document Type: Article

References (29)

1. Ryden L, Standl E, Bartnik M, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J. 2007;28:88-136
2. CBO/NHG. Multidisciplinaire Richtlijn Cardiovasculair risicomanagement, 2006. Available at: www.cbo.nl/product/richtlijnen/folder20021023121843/rl-cvrm- 2006.pdf/view [Last accessed 1 October 2008]
3. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-1389
4. Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361:1149-1158 (Pubitemid 36398384)
5. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301-1307
6. Anonymous. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22
7. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 2003;326:1423
8. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-1278
9. Kjekshus J, Apetrei E, Barrios V, et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007;357:2248-2261 (Pubitemid 350190755)
10. Tavazzi L, Maggioni AP, Marchioli R, et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008;372:1231-1239
11. Raina A, Pickering T, Shimbo D. Statin use in heart failure: a cause for concern? Am Heart J 2006;152:39-49
12. Fonarow GC. Randomized clinical outcome trials of statins in heart failure. Heart Fail Clin 2008;4:225-229
13. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195-2207
14. Hayward RA, Hofer TP, Vijan S. Narrative review: lack of evidence for recommended low-density lipoprotein treatment targets: a solvable problem. Ann Intern Med 2006;145:520-530 (Pubitemid 46780956)
15. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-1504 (Pubitemid 38477774)
16. de Lemos JA, Blazing MA, Wiviott SD, et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 2004;292:1307-1316
17. Pedersen TR, Faergeman O, Kastelein JJ, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 2005;294:2437-2445 (Pubitemid 41627921)
18. Avorn J. In defense of pharmacoepidemiology - embracing the yin and yang of drug research. N Engl J Med 2007;357:2219-2221
19. Penning-van Beest FJ, Termorshuizen F, Goettsch WG, et al. Adherence to evidence-based statin guidelines reduces the risk of hospitalizations for acute myocardial infarction by 40%: a cohort study. Eur Heart J 2007;28:154-159 (Pubitemid 46269874)
20. Dieleman JP, van Wyk JT, van Wijk MA, et al. Differences between statins on clinical endpoints: a population-based cohort study. Curr Med Res Opin 2005;21:1461-1468 (Pubitemid 41368579)
21. Rasmussen JN, Chong A, Alter DA. Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA 2007;297:177-186 (Pubitemid 46089734)
22. Foody JM, Joyce AT, Rudolph AE, et al. Cardiovascular outcomes among patients newly initiating atorvastatin or simvastatin therapy: a large database analysis of managed care plans in the United States. Clin Ther 2008;30:195-205
23. Jones PH, Hunninghake DB, Ferdinand KC, et al. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial. Clin Ther 2004;26:1388-1399
24. Bullano MF, Wertz DA, Yang GW, et al. Effect of rosuvastatin compared with other statins on lipid levels and National Cholesterol Education Program goal attainment for low-density lipoprotein cholesterol in a usual care setting. Pharmacotherapy 2006;26:469-478
25. Fox KM, Gandhi SK, Ohsfeldt RL, et al. Effectiveness of rosuvastatin in lowdensity lipoprotein cholesterol lowering and National Cholesterol Education Program Adult Treatment Panel guideline III LDL-C goal attainment compared to other statins among diabetes mellitus patients: a retrospective study using an electronic medical records dataset in the United States. Curr Med Res Opin 2007;23:2125-2133
26. Catalan V, Lelorier J. Predictors of long-term persistence on statins in a subsidized clinical population. Value in Health 2000;3:417-426 (Pubitemid 32066649)
27. Goettsch WG, Yin DD, Alemao E, et al. Statins are less effective in common daily practice among patients with hypercholesterolemia: the REALITY-PHARMO study. Curr Med Res Opin 2004;20:1025-1033 (Pubitemid 38954465)
28. Breslow NE, Day NE. Statistical methods in cancer research. Volume II - The design and analysis of cohort studies. IARC Sci Publ 1987;82:1-406
29. Heintjes EM, Hirsch MW, van der Linden MW, et al. LDL-C reductions and goal attainment among naïve statin users in the Netherlands: real life results. Curr Med Res Opin 2008;24:2241-2250